Botulinum toxin injections as a method for chemically denervating skeletal muscle to test functional hypotheses: a pilot study in Lepomis cyanellus by O'Neill, Matthew W. & Gibb, Alice C.
241
T E C H N I C A L C O M M E N T
Botulinum Toxin Injections as a Method for Chemically Denervating
Skeletal Muscle to Test Functional Hypotheses: A Pilot Study in
Lepomis cyanellus
Matthew W. O’Neill*
Alice C. Gibb
Department of Biological Sciences, Northern Arizona
University, Flagstaff, Arizona 86011
Accepted 11/2/2006; Electronically Published 1/3/2007
ABSTRACT
In this study, we demonstrate that botulinum toxin can be used
to chemically denervate muscles to test functional hypotheses.
We injected research-grade type A botulinum toxin complex
into pectoral fin abductors (abductor superficialis) of green
sunfish (Lepomis cyanellus) to determine whether chemical de-
nervation would eliminate the ability of a particular muscle to
contribute to overall pectoral fin movements. Reduction of
target muscle activity occurred within 8 d of the injection, and
paralysis was confirmed using electromyography. No paralysis
was seen in the adjacent muscles (abductor profundus) or in
positive controls (saline injections). Paralysis occurred more
slowly and at lower doses than previously documented for
mammals. However, botulinum toxin complex (500 kDa) was
used here, whereas previous studies have used purified toxin
(150 kDa). Therefore, differences in physiological responses
between fish and mammals cannot yet be distinguished from
differences caused by the toxin type. However, we note that
the toxin complex is less likely to diffuse across muscle fascia
(because it is large), which should minimize paralytic effects
on adjacent muscles. We suggest that botulinum toxin holds
great promise as a chemical denervation agent in functional
studies of animal locomotion and feeding behaviors.
Introduction
Functional morphologists and comparative anatomists often
seek to determine the function of an individual muscle, but
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this can be difficult in complex systems. For example, 14 mus-
cles span the human femur-tibia (knee) joint (Saladin 2001).
All of these muscles may serve to extend the lower leg; thus,
identifying the specific action of an individual muscle can be
difficult. A variety of techniques has been used to test hypoth-
eses about muscle function, including measuring muscle activ-
ity using electromyography (EMG), measuring muscle length
changes with sonomicrometry, measuring muscle force using
force buckles attached to tendons or strain gauges mounted on
bones, and disabling the muscle by various methods, including
severing ligaments or tendons that transmit muscle force and
physically denervating the muscle by transecting nerves. Al-
though important information has been gained from studies
using these methods, the invasive nature of some techniques
may limit their effectiveness for testing functional hypotheses,
while others will not work with very small animals.
Chemical denervation is a potentially useful tool for studying
muscle function because injections are minimally invasive. Bot-
ulinum toxin type A (commonly sold as Botox [Allergan] or
Dysport [Ipsen]) is a zinc endopeptidase produced by the bac-
teria Clostridium botulinum that has been used for decades to
denervate individual muscles in mammalian systems (Simpson
1981; Schiavo et al. 1992; Brin 1997). In humans, Botox has
been used therapeutically for a variety of muscular diseases and
conditions, including hyperfunctional facial lines (Blitzer et al.
1997), spasmodic torticollis (Borodic et al. 1992), focal dystonia
(Brin et al. 1986), cerebral palsy (Calderon Gonzalez et al. 1994;
Chutorian et al. 1995; Denislic and Meh 1995), and muscle
spasticity (Chutorian and Root 1994), and has recently been
used as a cosmetic treatment to relax the muscles that cause
facial wrinkles (Huilgol et al. 1999; Lehrer and Benedetto 2005).
In addition to pharmacological work, botulinum toxin has also
been used to paralyze muscles for developmental studies and
nerve regeneration studies (Pytte and Suthers 2000; Landers et
al. 2002). For these purposes, the neurotoxin is injected into
the target muscle, where it diffuses through neuromuscular
junctions into presynaptic motor neurons and prevents the
release of acetylcholine from the presynaptic neuron (Gunder-
son 1980; Simpson 1981; DasGupta 1994; Brin 1997).
There are seven serotypes of botulinum toxin, each of which
targets a different structure in the neuromuscular system (Bor-
odic et al. 1992, 1994; Brin 1997; Aoki and Guyer 2001; Comella
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Figure 1. Line drawing (after Drucker and Jensen 1997) illustrating right-side pectoral fin abductor muscles in Lepomis cyanellus. A, Right
lateral aspect of the pectoral fin abductor muscles after removal of the skin. B, Right lateral aspect with the abductor superficialis removed.
location of injection of toxin into the right abductor superficialis.xp approximate
and Pullman 2004; Gracies 2004). Type A toxin, the most com-
monly used toxin for medical procedures, destroys the SNAP-
25 protein, one of the proteins that enables neurotransmitter
vesicles to fuse to the presynaptic cell membrane and release
acetylcholine into the synaptic cleft (Schiavo et al. 1993). Mus-
cle deactivation in mice and rabbits may appear immediately;
however, it takes 3–4 d for complete paralysis to occur, and
paralysis in human treatments may take up to 7 d (Pearce et
al. 1995; Brin 1997). Motor neurons will eventually sprout new
terminal butons, which will restore nerve function and muscle
activity (Alderson et al. 1991). Recovery of muscle function in
mice and rabbits typically takes 4–6 mo; recovery takes ap-
proximately 3 mo in humans (Habermann 1974; Girlanda et
al. 1992; Borodic et al. 1994; Brin 1997) but can be more rapid
with lower toxin doses (Pearce et al. 1995). A side effect of
botulinum toxin paralysis is that muscles can show atrophy
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Figure 2. Line drawings illustrating a dorsal view of treated Lepomis
cyanellus during station holding. On the side where botulinum toxin
compound was injected (right), the pectoral fin extends approximately
35" from the midsaggital plane. On the side where saline solution (a
positive control) was injected (left), the pectoral fin extends approxi-
mately 90" from the midsaggital plane.
after treatment and fiber types may be different after recovery
(Ansved et al. 1997).
The effectiveness of botulinum toxin is determined by a
number of variables. Artificial stimulation of an injectedmuscle
has been shown to increase the effectiveness of the toxin in
rabbits (Kim et al. 2003), presumably by increasing the amount
of toxin taken up by the motor neurons. Because the spread
of the neurotoxin is limited (but not entirely blocked) by mus-
cle fascia (Shaari et al. 1991; George et al. 1992; Borodic et al.
1994; Eleopra et al. 1996), the injection dose, volume, location,
and the number of injections must be controlled to limit the
movement of the toxin into adjacent muscles (Lingua 1985;
Biglan et al. 1988; Borodic et al. 1992, 1994; Aoki and Guyer
2001; Comella and Pullman 2004; Gracies 2004). A higher
quantity of toxin and higher injected toxin solution volume
will increase muscle denervation but at the risk of regional or
systemic effects by diffusion into adjacent muscles and/or ax-
onal transport of the toxin (Habermann 1974; Girlanda et al.
1992; Borodic et al. 1994).
In this experiment, we use the relatively simple suite of mus-
cles that serve to abduct the pectoral fin in the green sunfish
Lepomis cyanellus (Rafinesque 1819) as a model system in which
to study botulinum toxin as a tool for chemical denervation.
Here, we denervate a target pectoral fin muscle using research-
grade type A botulinum toxin complex and confirm the de-
nervation using EMG to monitor muscle activity during
station-holding behavior. We demonstrate that botulinumtoxin
effectively eliminates electrical activity of the muscle and thus
removes the ability of the muscle to produce active force during
the fin beat cycle. This is a unique and valuable application of
botulinum toxin as a tool for functional morphology.
Material and Methods
Four green sunfish Lepomis cyanellus were obtained from Fossil
Creek, Arizona, by electrofishing. Fish ranged in standard
length from 87 to 138 mm (40.1–90.0 g) and were housed in
38-L aquaria at C. All animal care and experimental21"# 2"
procedures were conducted in accordance with Northern Ar-
izona University Institutional Animal Care and Use Committee
protocol 04-007.
An initial set of observations was made on untreated fish to
determine the baseline electrical activity of the paired muscles
during station-holding behavior. For these experiments, bipolar
hook electrodes were made from bifilar wire (stainless steel,
0.002 in; California Fine Wire Company, Grover Beach). In-
dividual green sunfish were anesthetized using tricane meth-
anosulfate (0.15 L water), and two or three scales wereg/1
removed to facilitate the placement of each electrode. After
external morphological landmarks (e.g., base of the pectoral
fin rays) were used to determine the appropriate implantation
location (Fig. 1), electrodes were inserted into the belly of each
muscle using 27-ga, 0.5-in syringe needles. Electrodes were im-
planted into two muscles on each side of the fish: the abductor
superficialis and the abductor profundus (Fig. 1). Both muscles
serve to abduct and depress the pectoral fin during steady swim-
ming and are active concomitantly during locomotion in many
fish species (Westneat 1996; Drucker and Jensen 1997; Westneat
and Walker 1997). Because of this simultaneous activity, distinct
functions for each muscle cannot readily be determined from
kinematic studies and EMG recordings.
After surgery, fish were returned to their home aquaria and
allowed to recover for 1–2 h. During this time, electrode leads
were attached to an A-M Systems model 1700 amplifier (low
cutoff 100 Hz, high cutoff 1,000 Hz), which amplified EMG
signals, and a MacLab 4e system captured and recorded EMG
signals at 1,000 Hz. Simultaneous EMG recordings were made
from the abductor superficialis and abductor profundus from
the left and right sides of each fish. Observations of fish be-
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Figure 3. Representative rectified electromyography signals of four pectoral fin muscles in Lepomis cyanellus during station holding. LPp
abductor profundus, abductor superficialis, abductor profundus, and abductor superficialis. A, Untreatedleft LSp left RPp right RSp right
sunfish (sunfish A) showing asynchronous electrical activity in the right- and left-side pectoral fin abductors. B, Treated sunfish (sunfish C)
showing synchronous electrical activity in the right- and left-side pectoral fin abductors. C, Treated sunfish (sunfish E) showing asynchronous
electrical activity in the right- and left-side pectoral fin abductors. D, Treated sunfish (sunfish D) showing asynchronous electrical activity in
the right- and left-side pectoral fin abductors and low-level activity in the right abductor superficialis.
havior were also made for two individuals with a JVC GR-DVL
9800 camera recording at 60 Hz to obtain dorsal views of fish
station holding in the tank. After the experiment, EMG signals
were filtered with a Butterworth filter (threshold 0.05 V, high
cutoff 500 Hz, low cutoff 100 Hz) using a custom LabView
program (Stephen Deban, University of South Florida, Tampa).
Subsequently, another set of experiments was conducted us-
ing type A botulinum toxin complex to chemically denervate
a target muscle. Despite its frequent and long-standing use in
human subjects, both the toxicity of solutions and the con-
centrations of botulinum toxin necessary to induce muscle pa-
ralysis are relatively unstandardized (Brin and Blitzer 1993; Brin
et al. 1993; Pearce et al. 1995; Brin 1997). “Mouse units” (MUs;
i.e., mouse LD50) is the accepted terminology for toxicity, but
MUs differ for the same mass of a given toxin isolated by
different companies. Therefore, different isolates of toxin yield
different physiological results, even when the two major com-
mercial type A toxins (Botox and Dysport) are compared
(Pearce et al. 1995; Brin 1997). Furthermore, there are differ-
ences in the relative toxicity of a given isolate across species
(Brin 1997) and even individuals (Pearce et al. 1995), which
means that caution must be used when extrapolating dosages
from one species to another (Brin 1997). For these reasons,
when working with botulinum toxin, it is critical to report
where the toxin is obtained, the injected amount, as well as
injection (ng/mL) and muscular (ng/muscle mg) concen-
trations.
For this study, type A botulinum toxin complex was pur-
chased from Metabiologics (Madison, WI). The complex is a
less expensive, unpurified form of the type A toxin and has six
associated proteins that serve to extend the shelf life of the
toxin and increase its molecular weight to 500 kDa. The bot-
ulinum complex’s toxicity is identified by http://www
.metabiologics.com as 1 MU/0.25 ng of toxin. A study assessing
the paralytic ability of Botox and Dysport in mice (Pearce et
al. 1995) found that approximately 0.7 MU of Botox toxin
would paralyze (i.e., reduce the compound action potential of
the muscle to 10% of baseline or less) a muscle weighing 0.1
g. Because the efficacy of the toxin as a muscle paralytic on
aquatic, poikilothermic vertebrates had never been established,
we began our pilot experiments with a very low toxin concen-
tration and progressively increased the dose to approximately
0.4 MU (0.1 ng) of toxin per 0.1 g muscle, at which point
muscle paralysis was achieved within 10 d. After we established
the appropriate dosage, we injected 0.3–0.4 MU of type A bot-
ulinum toxin complex (diluted in teleost saline to a final volume
of 1.5 or 2 mL, depending on the size of the animal) into the
right-side abductor superficialis (our target muscle) for three
individuals (hereafter, treated fish). As a positive control, we
injected 1.5 or 2 mL of teleost saline into the left-side abductor
superficialis of all three treated fish. Because the abductor su-
perficialis masses ranged from 0.06 to 0.12 g in our treated
animals (determined by removing and weighing the muscles
after the experiments), final injected concentrations ranged
from 3.0 to 6.8 MU/g muscle.
Approximately 1 wk after injection of the toxin complex, we
inserted electrodes and recorded EMG activity (using methods
described above) in the four fin abductor muscles while the
fish were holding station inside their tanks. To estimate the
time course for recovery in this species, one fish was held for
several weeks after the experiment until full pectoral fin move-
ment reappeared. All other fish were killed immediately fol-
lowing EMG recordings to confirm electrode placement.
To determine the effects of botulinum toxin on muscle ac-
tivity, we quantified a number of variables for all four muscles
in two baseline (untreated) and three treated fish (injected with
toxin and a positive control). Burst frequency of each muscle
was determined by calculating the time period in which three
sequential bursts occurred (beginning with the untreated left
abductor superficialis) in an arbitrarily selected section of the
EMG recording where fish were station holding and activity
was anticipated for all four pectoral fin abductors. Onset of
muscle activity was defined as electrical signal greater than two
times the background electrical activity (noise) lasting for more
than 10 ms, and offset was defined as the end of activitymeeting
these requirements. The relevant time interval was measured
from onset of the first burst to offset of the last burst for each
individual muscle; thus, three bursts divided by the time period
for these bursts yielded burst frequency (Hz). Burst frequency
was determined for each fish for three arbitrarily selected pe-
riods of muscle activity, which were separated from each other
by distinct periods of inactivity (i.e., no electrical activity).
Frequency data were examined using a series of ANOVAs
(JMP IN, ver. 5.1) to identify potential differences between
muscles (the four pectoral fin abductors) and treatment effects.
A one-way ANOVA examined the data for potential frequency
differences among muscles in untreated fish. A second one-
way ANOVA examined the data for potential differences among
muscles in treated fish. For both ANOVAs, Tukey-Kramer HSD
post hoc tests were used to determine which muscles were
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Figure 4. Mean burst frequencies (Hz) with standard error for each
muscle in two untreated (filled bars) and three treated (open bars) fish;
for each individual, three periods of muscle activity were examined.
abductor profundus, abductor superficialis,LPp left LSp left
abductor profundus, and abductor super-RPp right RSp right
ficialis.
significantly different from one another in burst frequency. To
examine the data for differences in muscle activity across treat-
ment, four one-way nested ANOVAs (individual nested within
treatment) were used to examine each of the four muscles for
potential treatment effects. For all ANOVAs, a P value less than
0.05 was considered significant.
Results
During the recovery period, fish were observed daily to deter-
mine the time course of the toxin complex’s effects. Between
3 and 5 d following injection, we noted a disruption of certain
behaviors in treated fish. Although feeding and prey-tracking
abilities remained largely unaffected, treated fish preferred to
rest on the bottom of the tank and rarely held station midwater
voluntarily. However, temporary station holding could be elic-
ited by providing the fish with food or gently prodding them
to leave the bottom.
Video recordings made of treated fish indicated that the pec-
toral fin on the side of the fish treated with the toxin did not
move as far anteriorly during station holding as the pectoral
fin on the untreated side. For example, one fish extended its
untreated fin approximately 90" out from its body but extended
its treated fin only approximately 35" (Fig. 2). During periods
of time when the fish were station holding, we also observed
apparent compensation for the lost range of motion with in-
creased frequency and amplitude in movements of the dorsal,
caudal, and anal fins.
Electromyographic recordings made of station-holding be-
havior in untreated individuals yielded patterns of muscle ac-
tivity similar to those reported in studies of pectoral fin lo-
comotion in other taxa (Westneat 1996; Drucker and Jensen
1997; Westneat and Walker 1997). For station holding, the left
abductor superficialis and abductor profundus muscles are ac-
tive simultaneously and show asynchronous periods of activity
relative to the right-side muscles (Fig. 3A). Following toxin
injection, the station-holding behavior is disrupted such that
the asynchronous fin beat becomes inconsistent and the left
and right muscles are active synchronously (Fig. 3B) as often
as they are asynchronously (Fig. 3C). One fish treated with
botulinum toxin complex did show some activity in the treated
muscle (right abductor superficialis), but the activity appeared
greatly reduced in magnitude relative to the paired untreated
muscle in the same fish (left abductor superficialis) and the
same muscle in untreated fish (Fig. 3D).
In the untreated fish that served to document baselinemuscle
activity, the mean frequency of burst activity did not differ
significantly among all four muscles (3.6 Hz; ). InFp 0.0496
posttreatment individuals, the frequency of burst activity did
not differ significantly for the two unmanipulated muscles
(right and left abductor profundus) and the muscle that served
as the positive control (left abductor superficialis; 3.5 Hz;
). However, the muscle that received a botulinumFp 0.0698
toxin injection (right abductor superficialis) showed signifi-
cantly reduced activity (Fig. 4; 0.2 Hz; ). The fourFp 23.1010
nested ANOVAs revealed a significant treatment effect for the
right abductor superficialis but not for the other three muscles
(Table 1; Fig. 4).
Discussion
Behavioral observations of both fish station holding and burst
frequency of pectoral fin muscles demonstrate that the abductor
superficialis was chemically denervated during this experiment.
After treatment with botulinum toxin complex, the fish showed
a change in pectoral fin movements on the affected side during
station-holding behavior, with little or no electrical activity in
the targeted abductor superficialis. We conclude that the fish
were no longer able to voluntarily stimulate this muscle with
the motor neurons; thus, the muscle was unable to contract
and produce force.
These data suggest that the abductor superficialis muscle can
be chemically denervated with little effect on the adjacent ab-
ductor profundus. In fact, although we were not able to quantify
this pattern because of the nature of our equipment (1,000-Hz
capture rate is too slow to allow accurate measurements of
rectified integrated area), there appears to be an increase in
magnitude of abductor profundus activity on the denervated
side (Fig. 3). We suggest that increased motor unit recruitment
in the abductor profundus may compensate for the loss of the
abductor superficialis. We also observed increased use of other
fins during station-holding behavior, including the use of the
dorsal and anal fins, presumably to compensate for the reduced
effectiveness of the pectoral fin.
This study demonstrates that type A botulinum toxin com-
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Table 1: Mean (Hz # SE) of muscle activity and F statistics from four
one-way nested ANOVAs
LP LS RP RS
Pretreatment 3.56 # .06 3.44 # .03 3.72 # .17 3.81 # .19
Posttreatment 3.58 # .32 3.55 # .34a 3.38 # .42 .23 # .23b
F statistic:
Treatment .0006 .0161 .2363 33.9965
Individual .2054 .2408 .6253 .2864
Note. Muscle activity shown in muscle bursts per second. ANOVAs were with individual
nested within treatment. abductor profundus, abductor superficialis,LPp left LSp left
abductor profundus, and abductor superficialis.RPp right RSp right
a Muscle injected with saline.
b Muscle injected with botulinum toxin.
plex can be used to selectively denervate a target muscle in a
teleost fish, with little or no effect on the surrounding muscles.
In addition, we note that denervation of the muscle caused a
suite of behavioral changes in the animal that, under more
controlled circumstances, could be used to elucidate muscle
function. For example, treated fish showed asymmetry in fin
abduction after the right-side abductor superficials was injected
with botulinum toxin. As denervation of this muscle yielded
decreased fin abduction, it appears this muscle may be re-
sponsible for the anteriormost excursion of the fin during
swimming. Thus, we propose that this methodology may be
successfully employed in future functional studies in teleost
fishes and other vertebrates where traditional methods of de-
termining muscle function are impractical.
There are some potential concerns with using botulinum
toxin for chemical denervation. One potential problem that has
been noted in previous studies is the ability of the toxin to
diffuse out of the target muscle and into adjacent muscles
(Shaari et al. 1991; George et al. 1992; Borodic et al. 1994;
Eleopra et al. 1996), although developmental studies in finches
and rats have effectively tested developmental hypotheses (Pytte
and Suthers 2000; Landers et al. 2002). We propose that using
research-grade botulinum toxin complex on nonhuman ver-
tebrates, instead of the purified neurotoxin required for human
use, may reduce or eliminate this problem. The botulinum
toxin complex consists of six proteins plus the toxin protein
(Brin 1997) and is approximately 500 kDa in size—whereas
the purified neurotoxin is only 150 kDa. On the basis of cy-
toplasmic diffusion rates of other proteins (Arrio-Dupont et
al. 2000), the passive diffusion rate of the toxin complex
through muscle cytoplasm may be as much as three orders of
magnitude less than that of the smaller, purified toxin. This
implies that higher concentrations of the complex can be in-
jected with little or no diffusion of the toxin complex out of
the target muscle, which would allow complete paralysis of the
target muscle without affecting adjacent muscles.
In addition to possible diffusion between muscles, there are
other potential drawbacks to using botulinum toxin that have
been observed in previous studies. The toxin can travel up
motor neurons into the central nervous system, and thus the
effects could potentially spread to other muscles or organ sys-
tems (Habermann 1974; Girlanda et al. 1992; Borodic et al.
1994), although we did not see evidence of this in our study.
There is also some evidence that repeated injections create re-
sistance to the toxin through antibodies (Greene et al. 1994;
Jankovic and Schwartz 1995; Kessler and Benecke 1997), al-
though limiting injections to one per experimental animal
should avoid this problem. Finally, the positive correlation be-
tween frequency of muscle activity and completeness of pa-
ralysis (Hughes and Whaller 1962; Nathan et al. 1985; Kim et
al. 2003) makes it likely that an infrequently used muscle will
not be paralyzed as effectively as a continuously active muscle,
although artificial stimulation of the targeted muscle may be
employed to circumvent this potential problem (Kim et al.
2003).
We also noted two differences in the efficacy of the toxin in
our study when compared with previous studies in mammalian
systems. First, a considerably smaller amount of toxin was re-
quired for full paralysis in fish (0.4 MU) than in mammals (0.7
MU). Second, we observed a slower time to complete paralysis
(7–9 d) than expected from mammalian studies (3–4 d). These
discrepancies could be caused by any of a number of factors.
(1) The toxin compound used here is larger in size than that
used in previous studies. It is possible that keeping the toxin
with its associated proteins improves the ability of the toxin to
remain intact in the muscle, allowing effective paralysis to occur
at lower doses. The associated proteins may also reduce the
ability of the toxin to diffuse throughout the muscle, which
may extend the time course required to paralyze the muscle.
(2) Ectotherms have substantially lower metabolic rates than
endotherms. A lower metabolic rate may contribute to a slower
time to complete paralysis (because the rate of toxin uptake
by the motor neuron will be lower), but it is not clear that a
low metabolic rate would explain differences in sensitivity to
the toxin. (3) Our experimental system was at a lower tem-
perature (22"C) than mammalian studies (39"C); increased
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temperature will increase diffusion and metabolic rates. As
above, this effect would likely contribute to a slower time to
complete paralysis in our system but not to the increased sen-
sitivity to the toxin. (4) It is possible that fish use their fins
less frequently than mammals used the locomotor muscles ex-
amined in previous studies. However, our fish muscles operated
at about 3.5 Hz during station holding, whereas previous studies
using artificial stimulation to enhance toxin uptake in rabbits
stimulated muscles at only 0.1 Hz (Kim et al. 2003). In addition,
we expect fish (which are continuously swimming) to use their
locomotor muscles more often than mammals (which can lie
on the ground or stand using postural muscles). We suggest
that fish use the injected muscle more than injected mammals
in any previous study and therefore consider this fourth pos-
sibility unlikely. Clearly, future studies comparing purified toxin
and toxin complex in fishes will be necessary to distinguish
potential phylogenetic physiological effects, temperature effects,
and frequency-of-use effects from effects due to differences in
the type of toxin compound injected.
We conclude that botulinum toxin is a tractable tool for
examining muscle function in vertebrates. However, additional
research is necessary to (1) clarify the ramifications of using
botulinum toxin complex instead of the purified toxin and (2)
determine the appropriate dosages to use for animals from
different vertebrate groups because metabolism and/or muscle
physiology may determine the susceptibility of a given group.
In addition, botulinum toxin may not be useful in targeting
very deep muscles because puncturing an overlying musclewith
the needle delivering the toxin to an underlying muscle will
likely render the incidentally punctured muscle more suscep-
tible to the effects of the toxin (because the toxin will more
readily diffuse across ruptured fascia; Shaari et al. 1991). How-
ever, for small muscles or muscle systems that cannot be studied
using more traditional techniques, chemical denervation holds
great promise for use in functional studies.
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